drugset / Trial / NCT02409004

Effects of Rifampin on the Pharmacokinetics of Ataluren

NCT02409004

Phase 1 Completed 15 enrolled PTC Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

This will be a single centre, Phase I, open-label, one cohort, one dose level, fixed-sequence, drug interaction study in healthy volunteers. The objective of this study is to determine the effects of rifampin on the pharmacokinetics of ataluren under fasting conditions.

Timeline

Start
2015-02
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ataluren Small molecule 1375 mg Oral
Subject Rifampin Small molecule 300 mg Oral

Indications

No indication recorded.